About pharmacyte biotech - PMCB
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Las Vegas, NV.
PMCB At a Glance
PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway
Las Vegas, Nevada 89169
| Phone | 1-917-595-2850 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Other | Net Income | -19,424,654.00 | |
| Sector | Health Technology | Employees | 2 | |
| Fiscal Year-end | 04 / 2027 | |||
| View SEC Filings |
PMCB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.233 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 5.611 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PMCB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -9,712,327.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PMCB Liquidity
| Current Ratio | 45.28 |
| Quick Ratio | 45.28 |
| Cash Ratio | 44.872 |
PMCB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -38.117 |
| Return on Equity | -44.936 |
| Return on Total Capital | -56.199 |
| Return on Invested Capital | -44.936 |
PMCB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |